873970-07-1

Basic information

• Product Name: ethyl 7-methoxy-4-oxo-2-phenyl-1,4-dihydroquinoline-3-carboxylate
• CAS NO: 873970-07-1
• Molecular Weight: 323.348
• Mol File: 873970-07-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: ethyl 7-methoxy-4-oxo-2-phenyl-1,4-dihydroquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 7-methoxy-4-oxo-2-phenyl-1,4-dihydroquinoline-3-carboxylate(873970-07-1)
• EPA Substance Registry System: ethyl 7-methoxy-4-oxo-2-phenyl-1,4-dihydroquinoline-3-carboxylate(873970-07-1)

Safety Data

• Hazardous Substances Data: 873970-07-1(Hazardous Substances Data)

Upstream product

• 80819-63-2 N-(3-methoxy-phenyl)-benzimidoyl chloride 
• 996-82-7 sodium diethylmalonate 
• 5877-59-8 N-benzylidene-m-anisidine 
• 1226760-29-7 C₁₃H₁₂ClNO₄ 
• 56881-19-7 Diethyl 2-<(3-methoxyphenylamino)methylene>malonate 
• 536-90-3 m-Anisidine 
• 77156-85-5 Ethyl 4-chloro-7-methoxyquinoline-3-carboxylate 
• 71083-05-1 7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 

Downstream Products

• 873383-40-5 4-hydroxy-7-methoxy-2-phenyl-quinoline-3-carboxylic acid 
• 20430-72-2 7-methoxy-2-phenylquinolin-4-ol 
• 189816-05-5 4-chloro-7-methoxy-2-phenylquinoline 

Relevant articles and documents

Lead optimization of 3-carboxyl-4(1 H)-quinolones to deliver orally bioavailable antimalarials

Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.